Moderna, Inc. Common Stock MRNA
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T04:22:15.611Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T00:59:39.153430768Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-10T00:12:00.739328+00:00
Earnings observationsAlpha Vantage · collected 2026-11-10T00:11:48.761378+00:00
Moderna, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 275.93 | 107.5% | 10.1% | 232.18 | 120.2% | 9.5% |
| 25Δ | 270.86 | 104.2% | 8.4% | 236.93 | 116.1% | 8.0% |
| 30Δ | 267.33 | 106.3% | 7.5% | 240.42 | 119.5% | 7.1% |
| 35Δ | 263.45 | 103.6% | 6.3% | 243.96 | 120.9% | 6.3% |
| 40Δ | 260.17 | 102.9% | 5.4% | 247.48 | 122.7% | 5.5% |
| 45Δ | 257.06 | 102.7% | 4.6% | 251.02 | 122.1% | 4.8% |
| 50Δ | 254.11 | 103.4% | 4.0% | 254.51 | 121.2% | 4.1% |
| 55Δ | 251.13 | 101.7% | 3.3% | 258.07 | 121.5% | 3.5% |
| 60Δ | 248.19 | 101.7% | 2.8% | 262.04 | 124.9% | 3.0% |
| 65Δ | 245.05 | 103.9% | 2.4% | 265.50 | 121.0% | 2.4% |
| 70Δ | 242.34 | 98.8% | 1.8% | 269.30 | 119.2% | 1.9% |
| 75Δ | 238.86 | 100.8% | 1.5% | 276.16 | 131.6% | 1.6% |
| 80Δ | 236.36 | 93.9% | 1.0% | 284.25 | 141.8% | 1.3% |
20Δ
- Pseudo strike
- 275.93
- IV
- 107.5%
- B/E move
- 10.1%
- Pseudo strike
- 232.18
- IV
- 120.2%
- B/E move
- 9.5%
25Δ
- Pseudo strike
- 270.86
- IV
- 104.2%
- B/E move
- 8.4%
- Pseudo strike
- 236.93
- IV
- 116.1%
- B/E move
- 8.0%
30Δ
- Pseudo strike
- 267.33
- IV
- 106.3%
- B/E move
- 7.5%
- Pseudo strike
- 240.42
- IV
- 119.5%
- B/E move
- 7.1%
35Δ
- Pseudo strike
- 263.45
- IV
- 103.6%
- B/E move
- 6.3%
- Pseudo strike
- 243.96
- IV
- 120.9%
- B/E move
- 6.3%
40Δ
- Pseudo strike
- 260.17
- IV
- 102.9%
- B/E move
- 5.4%
- Pseudo strike
- 247.48
- IV
- 122.7%
- B/E move
- 5.5%
45Δ
- Pseudo strike
- 257.06
- IV
- 102.7%
- B/E move
- 4.6%
- Pseudo strike
- 251.02
- IV
- 122.1%
- B/E move
- 4.8%
50Δ
- Pseudo strike
- 254.11
- IV
- 103.4%
- B/E move
- 4.0%
- Pseudo strike
- 254.51
- IV
- 121.2%
- B/E move
- 4.1%
55Δ
- Pseudo strike
- 251.13
- IV
- 101.7%
- B/E move
- 3.3%
- Pseudo strike
- 258.07
- IV
- 121.5%
- B/E move
- 3.5%
60Δ
- Pseudo strike
- 248.19
- IV
- 101.7%
- B/E move
- 2.8%
- Pseudo strike
- 262.04
- IV
- 124.9%
- B/E move
- 3.0%
65Δ
- Pseudo strike
- 245.05
- IV
- 103.9%
- B/E move
- 2.4%
- Pseudo strike
- 265.50
- IV
- 121.0%
- B/E move
- 2.4%
70Δ
- Pseudo strike
- 242.34
- IV
- 98.8%
- B/E move
- 1.8%
- Pseudo strike
- 269.30
- IV
- 119.2%
- B/E move
- 1.9%
75Δ
- Pseudo strike
- 238.86
- IV
- 100.8%
- B/E move
- 1.5%
- Pseudo strike
- 276.16
- IV
- 131.6%
- B/E move
- 1.6%
80Δ
- Pseudo strike
- 236.36
- IV
- 93.9%
- B/E move
- 1.0%
- Pseudo strike
- 284.25
- IV
- 141.8%
- B/E move
- 1.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 68.76% | |
| 67.51% | |
| 65.08% | |
| 68.47% | |
| 68.44% | |
| 194.02% | |
| 146.95% | |
| 110.44% | |
| 105.46% | |
| 109.65% | |
| 89.52% | |
| 81.09% | |
| 72.50% | |
| 81.80% | |
| 87.44% | |
| 80.67% | |
| 78.62% | |
| 70.14% | |
| 74.38% | |
| 70.99% | |
| 67.38% | |
| 69.55% | |
| 77.79% | |
| 75.80% | |
| 76.58% | |
| 78.97% | |
| 63.20% | |
| 80.49% | |
| 78.30% | |
| 78.47% | |
| 84.51% | |
| 79.24% | |
| 81.66% | |
| 83.98% | |
| 82.80% | |
| 81.07% | |
| 82.51% | |
| 89.94% | |
| 90.43% | |
| 88.61% | |
| 93.59% | |
| 102.12% | |
| 100.13% | |
| 103.19% | |
| 108.57% | |
| 112.31% | |
| 117.62% | |
| 131.66% | |
| 131.22% | |
| 133.89% | |
| 116.16% | |
| 102.15% | |
| 93.13% | |
| 99.72% | |
| 96.03% | |
| 93.31% | |
| 92.17% | |
| 102.26% | |
| 99.10% |
Biotechnology
MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human…
More →NAMS
NewAmsterdam Pharma Company N.V. is a forward-looking biotechnology firm focused on the development of innovative therapies for cardiometabolic diseases, leveraging its…
More →NAUT
Nautilus Biotechnology, Inc., a development-stage life sciences company, is dedicated to creating platform technology to quantify and unlock proteome complexity. The company is…
More →NBTX
Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.
More →NGNE
Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders, addressing significant unmet medical…
More →NKTR
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad,…
More →